Srikanth Chiliveru

R&d
Gurgaon, HR, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Cystathionine Beta-Synthase Promotes Anoikis Resistance and Transcoelomic Metastasis in Ovarian Cancer via the SP1-ITGB1 axis.

Cystathionine Beta-Synthase Promotes Anoikis Resistance and Transcoelomic Metastasis in Ovarian Cancer via the SP1-ITGB1 axis.

Journal: bioRxiv : the preprint server for biology

Published: December 25, 2025

Cystathionine beta-synthase promotes anoikis resistance and transcoelomic metastasis in ovarian cancer via SP1- ITGB1 regulation.

Cystathionine beta-synthase promotes anoikis resistance and transcoelomic metastasis in ovarian cancer via SP1- ITGB1 regulation.

Journal: Experimental hematology & oncology

Published: December 15, 2025

Targeting IL-23 for the interception of obesity-associated colorectal cancer.

Targeting IL-23 for the interception of obesity-associated colorectal cancer.

Journal: Neoplasia (New York, N.Y.)

Published: May 10, 2023

Molecular disparities in colorectal cancers of White Americans, Alabama African Americans, and Oklahoma American Indians.

Molecular disparities in colorectal cancers of White Americans, Alabama African Americans, and Oklahoma American Indians.

Journal: NPJ precision oncology

Published: March 08, 2023

Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report.

Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report.

Journal: Medicine

Published: February 22, 2020

Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy.

Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN® in combination with chemotherapy.

Journal: Future science OA

Published: December 13, 2019

A retrospective analysis comparing APCEDEN® dendritic cell immunotherapy with best supportive care in refractory cancer.

A retrospective analysis comparing APCEDEN® dendritic cell immunotherapy with best supportive care in refractory cancer.

Journal: Immunotherapy

Published: August 26, 2017

Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN® (dendritic cell-based vaccine): a case report.

Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN® (dendritic cell-based vaccine): a case report.

Journal: Clinical case reports

Published: May 31, 2017

Showing 1-8 of 8

Last Updated: 09/26/2026